KR970009579B1 - 서방제제 - Google Patents

서방제제 Download PDF

Info

Publication number
KR970009579B1
KR970009579B1 KR1019910015156A KR910015156A KR970009579B1 KR 970009579 B1 KR970009579 B1 KR 970009579B1 KR 1019910015156 A KR1019910015156 A KR 1019910015156A KR 910015156 A KR910015156 A KR 910015156A KR 970009579 B1 KR970009579 B1 KR 970009579B1
Authority
KR
South Korea
Prior art keywords
composition
high molecular
solubility
drug
poorly soluble
Prior art date
Application number
KR1019910015156A
Other languages
English (en)
Korean (ko)
Other versions
KR920003973A (ko
Inventor
야스시 모리따
아끼라 오오또리
마사꼬 안도오
Original Assignee
센쥬세이야꾸 가부시끼가이샤
요시다 쇼우지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 센쥬세이야꾸 가부시끼가이샤, 요시다 쇼우지 filed Critical 센쥬세이야꾸 가부시끼가이샤
Publication of KR920003973A publication Critical patent/KR920003973A/ko
Application granted granted Critical
Publication of KR970009579B1 publication Critical patent/KR970009579B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1019910015156A 1990-08-30 1991-08-30 서방제제 KR970009579B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP22988790 1990-08-30
JP229887/1990 1990-08-30
JP90-229887 1990-08-30

Publications (2)

Publication Number Publication Date
KR920003973A KR920003973A (ko) 1992-03-27
KR970009579B1 true KR970009579B1 (ko) 1997-06-14

Family

ID=16899272

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910015156A KR970009579B1 (ko) 1990-08-30 1991-08-30 서방제제

Country Status (10)

Country Link
US (1) US5183662A (ru)
EP (1) EP0474098B1 (ru)
JP (1) JP3934684B2 (ru)
KR (1) KR970009579B1 (ru)
AT (1) ATE102022T1 (ru)
CA (1) CA2050067C (ru)
DE (1) DE69101291T2 (ru)
DK (1) DK0474098T3 (ru)
ES (1) ES2062634T3 (ru)
RU (1) RU2053769C1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993019739A1 (en) * 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
FR2748205A1 (fr) 1996-05-06 1997-11-07 Debio Rech Pharma Sa Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
ES2221019T3 (es) 1996-10-31 2004-12-16 Takeda Chemical Industries, Ltd. Preparacion de liberacion mantenida.
KR100244164B1 (ko) * 1997-07-15 2000-03-02 김용옥 수용성 고분자-타크로리무스 접합체 화합물 및 그의 제조 방법
US6498153B1 (en) 1998-12-31 2002-12-24 Akzo Nobel N.V. Extended release growth promoting two component composition
JP2000281561A (ja) * 1999-03-26 2000-10-10 Ajinomoto Co Inc 新規溶媒法固体分散体製剤
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
DE10058772A1 (de) * 2000-11-27 2002-06-06 Falk Pharma Gmbh Verfahren zur Herstellung leicht löslicher Arzneimittelformulierungen und entsprechende Formulierungen
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
KR100446101B1 (ko) * 2000-12-07 2004-08-30 주식회사 삼양사 수난용성 약물의 서방성 제형 조성물
EP1408876A4 (en) 2001-06-22 2004-09-22 Durect Corp ZERO ORDER COAXIAL IMPLANTS WITH EXTENDED RELEASE
JP4679822B2 (ja) 2002-03-13 2011-05-11 ノバルティス アーゲー 医薬微粒子
WO2003077883A2 (de) * 2002-03-15 2003-09-25 Kuyus Stiftung Zusammensetzung und verwendung derselben zur bildung eines schutzfilms auf nasenschleimhäuten
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
CA2602525A1 (en) * 2005-03-21 2006-09-28 Macusight, Inc. Drug delivery systems for treatment of diseases or conditions
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
KR100816065B1 (ko) * 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
KR100871988B1 (ko) 2007-06-25 2008-12-05 한국과학기술원 수용성 용매 없이 수용성 거대분자 약물이 봉입된 생분해성미립구 담체의 제조방법 및 생분해성 미립구 담체
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
GB201119985D0 (en) * 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10806703B2 (en) * 2012-01-20 2020-10-20 Lts Lohmann Therapie-System Ag Transmucosal administration system for a pharmaceutical drug
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1391554A (en) * 1972-08-03 1975-04-23 Beecham Group Ltd Pharmaceutical compositions and process for their preparation
US4048256A (en) * 1976-06-01 1977-09-13 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
DE2856901D2 (de) * 1977-06-07 1980-11-13 Garching Instrumente Form of implant medicament and preparation process
GB2091554B (en) * 1981-01-13 1984-09-12 Mitsui Toatsu Chemicals Rod like moulded drug
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4666704A (en) * 1985-05-24 1987-05-19 International Minerals & Chemical Corp. Controlled release delivery system for macromolecules
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules

Also Published As

Publication number Publication date
JPH054924A (ja) 1993-01-14
JP3934684B2 (ja) 2007-06-20
DE69101291T2 (de) 1994-07-07
DE69101291D1 (de) 1994-04-07
KR920003973A (ko) 1992-03-27
CA2050067A1 (en) 1992-03-01
US5183662A (en) 1993-02-02
ATE102022T1 (de) 1994-03-15
DK0474098T3 (da) 1994-05-02
EP0474098A1 (en) 1992-03-11
CA2050067C (en) 2000-05-30
ES2062634T3 (es) 1994-12-16
RU2053769C1 (ru) 1996-02-10
EP0474098B1 (en) 1994-03-02

Similar Documents

Publication Publication Date Title
KR970009579B1 (ko) 서방제제
JP3265680B2 (ja) 経口製剤用組成物
JP2571693B2 (ja) フェノフィブレ−ト含有顆粒状医薬品及びその製法
JP4137179B2 (ja) 生物付着性物質としての脂肪酸エステルの使用
KR100348585B1 (ko) 다리페나신을함유하는약학제제
JP4841092B2 (ja) フェノフィブレート含有医薬組成物およびこれを調製するための方法
US5051263A (en) Controlled-release formulations
AT391806B (de) Verfahren zur herstellung einer festen dispersion eines pharmakologischen wirkstoffes in einer polymeren matrix
CS270560B2 (en) Method of biologically active compounds solubilization
JPH07215843A (ja) 生物学的付着性を有する徐放性薬理組成物
WO2002020037A1 (fr) Composition pharmaceutique a administration orale liberee au niveau colique
JPS6327439A (ja) 持続性薬効製剤
JPH07196513A (ja) 医薬顆粒
EP1154762B1 (en) Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
EP2902399B1 (en) Water-soluble derivatives and prodrugs of acacetin and methods of making and using thereof
US20020076444A1 (en) Novel method for obtaining microspheres and resulting products
JPH03130225A (ja) 易吸収性製剤用組成物
DE2950154C2 (ru)
JPH04305534A (ja) オーレオバシジン類製剤
JP2935117B2 (ja) ナノスフェア製剤
JPS63115817A (ja) 肝疾患治療薬組成物
US20040076682A1 (en) Novel ophthalmic compositions
JPH10505574A (ja) 乾燥製剤の製造方法と、この方法で得られる医薬組成物
CN112770750A (zh) 乙内酰脲衍生物的固体分散体
JPH07330582A (ja) 直腸投与用組成物

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011107

Year of fee payment: 5

LAPS Lapse due to unpaid annual fee